Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_assertion type Assertion NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_head.
- NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_assertion description "[Because CYP2D6 is known to be a key enzyme responsible for the generation of an active tamoxifen metabolite, 'endoxifen', some studies reported that genetic polymorphisms of CYP2D6 that reduced its enzyme activity or coadministration of CYP2D6 inhibitors were associated with the poor clinical outcomes of breast cancer patients treated with tamoxifen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_provenance.
- NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_assertion evidence source_evidence_literature NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_provenance.
- NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_assertion SIO_000772 21342038 NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_provenance.
- NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_assertion wasDerivedFrom befree-2016 NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_provenance.
- NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_assertion wasGeneratedBy ECO_0000203 NP874231.RALim6tXLp84ksKKcF6jg6T3N2jEUL2cIjORQw78paPlE130_provenance.